COHRMEDIUM SIGNALFINANCIAL10-K

COHR showed solid operational momentum with revenue growing 19% alongside meaningful increases in R&D investment and capital expenditures, though current liabilities expanded notably.

The company appears to be in a growth investment phase, with substantial increases in R&D spending and capital expenditures suggesting confidence in future opportunities. However, the 34% increase in current liabilities warrants monitoring to ensure it reflects operational growth rather than liquidity pressures.

Comparing 2025-08-15 vs 2024-08-16View on EDGAR →
FINANCIAL ANALYSIS

COHR delivered strong top-line growth of 19% to $1.2B while meaningfully expanding R&D investment by 22% to $582M, signaling aggressive investment in innovation. Operating cash flow grew 16% to $634M and capital expenditures increased 27% to $441M, indicating robust reinvestment in the business. The company reduced total debt by 10% to $3.7B while current liabilities jumped 34% to $1.8B, creating a mixed liquidity picture that suggests strong operational activity but requires careful monitoring.

FINANCIAL STATEMENT CHANGES
Current Liabilities
Balance Sheet
+33.6%
$1.3B$1.8B

Current liabilities surged 33.6% — significant near-term obligations; verify ability to meet short-term debt.

Capital Expenditure
Cash Flow
+27.1%
$346.8M$440.8M

Capex increased 27.1% — ongoing investment in capacity or infrastructure for future growth.

R&D Expense
P&L
+21.5%
$478.8M$581.9M

R&D investment increased 21.5% — signals commitment to future product development, though near-term margin impact.

Revenue
P&L
+19.2%
$972.0M$1.2B

Revenue growing 19.2% — solid top-line momentum, watch margins for quality of growth.

Operating Cash Flow
Cash Flow
+16.1%
$545.7M$633.6M

Operating cash flow grew 16.1% — strong conversion of earnings to cash, healthy business fundamentals.

Accounts Receivable
Balance Sheet
+13.6%
$848.5M$964.1M

Receivables grew 13.6% — monitor days sales outstanding for collection efficiency.

Inventory
Balance Sheet
+11.8%
$1.3B$1.4B

Inventory built 11.8% — monitor whether demand supports this build or if write-downs may follow.

Total Debt
Balance Sheet
-10.1%
$4.1B$3.7B

Debt reduced 10.1% — deleveraging strengthens balance sheet and reduces financial risk.

LANGUAGE CHANGES
NEW — 2025-08-15
PRIOR — 2024-08-16
ADDED
Number of outstanding shares of common stock, no par value, at August 11, 2025, was 155,805,474 .
Risks Related to Our Business, Operations and Industry Our competitive position depends on our ability to develop new products and processes and may require significant investment.
A significant portion of our business is subject to cyclical market factors and we may fail to accurately estimate the size and growth rate of our markets and our customers demands.
Any loss, cancellation, reduction, or delay in purchases by these large customers could harm the longevity of our business.
Products that fail to meet specifications, are defective, or are otherwise incompatible with end uses could impose significant costs on us.
+7 more — sign up free →
REMOVED
Number of outstanding shares of common stock, no par value, at August 13, 2024, was 153,300,385 .
Risks Relating to Our Business and Our Industry Investments in future markets of potential significant growth may not result in the expected return.
Our competitive position depends on our ability to develop new products and processes.
Our products may contain defects that are not detected until deployed, which could increase our costs, reduce our revenues, cause us to lose key customers, or expose us to litigation related to our products.
Our competitive position may require significant investments.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →